Book a Meeting

Non-Fucosylated Anti-Human Claudin 18 (iMAB362) Therapeutic Antibody (CAT#: BioBet-714ZP) Datasheet

Target
Claudin 18
Isotype
IgG1
Description
ADCC-Enhanced anti-Claudin 18 (iMAB362) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Gastric Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Claudin 18 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CLDN18
Full Name
claudin 18
Background
This gene encodes a member of the claudin family. Claudins are integral membrane proteins and components of tight junction strands. Tight junction strands serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets, and also play critical roles in maintaining cell polarity and signal transductions. This gene is upregulated in patients with ulcerative colitis and highly overexpressed in infiltrating ductal adenocarcinomas. PKC/MAPK/AP-1 (protein kinase C/mitogen-activated protein kinase/activator protein-1) dependent pathway regulates the expression of this gene in gastric cells. Alternatively spliced transcript variants encoding different isoforms have been identified.
Alternative Names
CLDN18; claudin 18; SFTA5; SFTPJ; claudin-18; surfactant associated 5; surfactant associated protein J; surfactant, pulmonary associated protein J
Gene ID
51208
UniProt ID
P19022
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CLDN18 include Bile Duct Cancer and Urachus Cancer.
Related Pathways
Its related pathways are Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling and Pathogenic Escherichia coli infection.
Function
Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.
Post-translational modifications
1.Glycosylation at Asn116 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
iMAB362
Host
Chimeric
Species Reactivity
Human
Description
Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. Preclinically, claudiximab was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytoxicity, antibody-dependent cellular cytotoxicity) and direct mechanisms (antiproliferative and proapoptotic effects).
Indication
Gastric Cancer

Gastric Cancer

Related Products

Non-Fucosylated Anti-Human Claudin 18 (zolbetuximab) Therapeutic Antibody (CAT#: BioBet-716ZP)
Non-Fucosylated Anti-Human Claudin 18 (claudiximab) Therapeutic Antibody (CAT#: BioBet-715ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany